Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  -6.00 -0.52% 1,150.00 168,170 16:29:48
Bid Price Offer Price High Price Low Price Open Price
1,150.00 1,151.00 1,157.00 1,148.00 1,151.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 259.90 56.40 22.00 52.3 2,364
Last Trade Time Trade Type Trade Size Trade Price Currency
17:42:45 O 227 1,152.242 GBX

Abcam (ABC) Latest News

More Abcam News
Abcam Takeover Rumours

Abcam (ABC) Share Charts

1 Year Abcam Chart

1 Year Abcam Chart

1 Month Abcam Chart

1 Month Abcam Chart

Intraday Abcam Chart

Intraday Abcam Chart

Abcam (ABC) Discussions and Chat

Abcam Forums and Chat

Date Time Title Posts
04/10/201920:46ABCAM with Charts & News141
19/11/201720:07Investing ? Start with your ABC's703
29/8/201323:08ABCAM - another e-Commerce Retailer120

Add a New Thread

Abcam (ABC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Abcam trades in real-time

Abcam (ABC) Top Chat Posts

Abcam Daily Update: Abcam Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ABC. The last closing price for Abcam was 1,156p.
Abcam Plc has a 4 week average price of 1,082p and a 12 week average price of 1,082p.
The 1 year high share price is 1,523p while the 1 year low share price is currently 1,006p.
There are currently 205,597,614 shares in issue and the average daily traded volume is 374,077 shares. The market capitalisation of Abcam Plc is £2,364,372,561.
mw8156: significant fall in the share price might result in it being taken over as the leading antibody company, their cash generative nature and their huge catalogue of 18000 validated antibodies and that would be Britain's only leading life sciences tools company disappearing which would be a shame after Illumina snapped up our sequencing technology.
erogenous jones: City did not like the figures. Sharp rises and sharp falls (in the share price) are normal for this company.
erogenous jones: Not in the least fussed about the drop yesterday, or the rise today, for that matter. Good, well managed and profitable company that has a track record of share price growth over many years. That was the case last week and remains the case this week. My average price is £6.50 and until the company ceases to be as profitable as in previous years I see no reason why I should not allow profits to run.
investorschampion: Milner's wife recently bought £2m worth of shares. It's a nice confidence booster following the recent share price weakness, but perhaps some executive directors should follow suit? hxxps://
jurgenklopp: With regards to the large PDMR purchase yesterday it should be noted that Milner sold over 1 million shares at £14.41 as recently as late September. However re-investing 2 million quid back in company shares ought to provide some kind of support to the share price in these strange times !!
shawzie: I can only agree with Panmure that the current share price overvalues this Company. Earnings fairly static on increasing turnover. Intangibles increasing rapidly, but not reflected in increased earnings. Increase in Net Worth of Company due mainly to increase in Intangibles. Does anyone have a more optimistic view?
campbed: Very good trading update today outlining progress on all fronts. A great British success story . Share price at 640p almost back to the all time high of 660p reached at end of 2015 before the market-wide Jan sell off.
apad: Slater in the Telegraph today - with any luck that should drive the share price down for those who are looking for an entry point. apad  . .R01;and some can be disastrous Other Aim shares that are favourites of veteran IHT investors are Young & Co’s Brewery, Advanced Medical Solutions and Abcam. All three are good sound companies but it seems to me that their share prices are living on the memory of their excellent past growth. Nowadays their p/e ratios are in or around the 20s with only single-digit earnings growth forecast. They are not for me because the slightest upset in their earnings growth could cause a major setback in their shares.
simon gordon: Unicorn AIM VCT - 20/5/14 Abcam (-23%) is a global leader in the supply of innovative protein research tools. In March 2014, Abcam released its financial results for the six month period ended 31 December 2013, which were in line with your Investment Manager's internal forecasts. Revenues of £61.9m (H2 2012: £57.3m) represented half-year on half-year growth of over 8%, while earnings per share were up 6.5% to 8.74p (H2 2012: 8.21p). Abcam remains a cash generative business with a robust balance sheet. Net cash balances at the period end amounted to £35.3m. Despite Abcam's many obvious qualities, market reaction to the release of Interim Results in early March was negative as investors worried about currency headwinds and the impact of possible cuts to health budgets in the key North American market, which accounts for 43% of total sales. As a result, Abcam's share price ended the period markedly lower. The holding has been retained in the portfolio in the expectation that the de-rating in the value of Abcam will prove to be temporary.
richscotsman: Buy into Abcam as share price drops, says Numis Antibody supplier Abcam (ABC.L) has been upgraded from 'hold' to 'buy' by Numis analyst Charles Weston. Weston placed a target price of 510p on the shares despite a sharp drop in the share price earlier in the week as it revealed sluggish Japanese growth despite the Japanese government investing in research. 'We are upgrading our recommendation to 'buy', from 'hold', following the sharp fall in the share price [on Wednesday morning],' he said. 'In our view little has changed in the fundamental investment thesis for Abcam and history has taught us that periods of weakness in its share price are the right time to buy into its highly defensive business model.' Weston said he 'expected margins and cash generation to remain high due to the characteristics of the product and Abcam's digital platform' and that management's investment in new growth initiatives has 'yet to translate to accelerating growth rates, which could start to be delivered over the next six-12 months'.
Abcam share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191018 17:03:57